The contract funded by NIH is valued up to €60m ($75m) and covers a ten year period.
Evotec chief operating officer Dr Mario Polywka said the NIH long term contract will further validate the company’s entry into compound management through the acquisition of Compound Focus.
"This long term contract will be managed through our San Francisco subsidiary however we are also currently developing options to expand our compound management capabilities into the East Coast of USA and also into Europe," Dr Polywka added.
The NIH SMR contract will carry on providing services to acquire, store, maintain, and distribute the current library collection, thereby supporting certain NIH-supported screening centers.
The contract resource will even be made available to select outside collaborators in addition to the NIH screening efforts/programs.
Library development efforts are expected to continue to shape and expand the collection.